409P - Effect of transdermal granisetron on prevention of nausea and vomiting during chemotherapy of lung cancer

Background

Chemotherapy is the basic treatments for lung cancer, and nausea and vomiting is one of the most common adverse event of chemotherapy, which decrease the life quality. As a result, how to prevent chemotherapy induced nausea and vomiting(CINV) is an important subject faced by oncologists. The granisetron transdermal delivery system (GTDS) has been developed to deliver granisetron continuously over 7 days to prevent CINV. Some previous cases receiving multiday highly emetogenic chemotherapy (HEC) regimens showed that the GTDS plus dexamethasone was not inferior to the GTDS plus dexamethasone and aprepitant. But there is no similar studies at home and abroad.

Methods

Our study prospectively assessed the non-inferiority of the GTDS plus dexamethasone to the GTDS plus dexamethasone and aprepitant in patients receiving multiday HEC. The primary endpoint was the proportion of patients with complete control of CINV from chemotherapy initiation until 24 h after final administration. The study has already enrolled 40 patients, 21 patients with two regimens, and 19 patients with three regimens before receiving multiday HEC.

Results

Between January 2019 and June 2020, 40 patients was recruited in the analysis. The GTDS plus dexamethasone group displayed non-inferiority to The GTDS plus dexamethasone and aprepitant group, complete control was achieved by 63.6% of patients in the two regimens group, and 65.4% in the three regimens group (P>0.05). Both treatments were well tolerated, the most common adverse events are manageable.

Conclusions

Current guidelines for the management of multiday HEC recommend three regimens therapy. Our study indicate that the two regimens therapy provides effective, well-tolerated control of multiday HEC. It offers a alternative route for delivering two regimens for up to 7 days that is as effective as three regimens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.